# A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

> **NCT05260021** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 99 (actual)

## Conditions studied

- Type2 Diabetes
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- T2D
- T2DM (Type 2 Diabetes Mellitus)
- Glucose Metabolism Disorders
- Endocrine System Diseases
- Metabolic Disease

## Interventions

- **DRUG:** Tirzepatide Dose 1
- **DRUG:** Tirzepatide Dose 2
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05260021
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-13
- **Primary completion:** 2024-07-30
- **Final completion:** 2025-01-28
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2025-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05260021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05260021, "A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05260021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*